CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant

Marcilio Jorge Fumagalli; Luiza Antunes Castro-Jorge; William Marciel de Souza; Patrick Orestes de Azevedo; Alana Witt Hansen; Ricardo Tostes Gazzinelli; Benedito Antônio Lopes da Fonseca; Fernando Rosado Spilki; Luiz Tadeu Moraes Figueiredo

doi:10.3390/v14020305

CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant

Marcilio Jorge Fumagalli, Luiza Antunes Castro-Jorge, William Marciel de Souza, Patrick Orestes de Azevedo, Alana Witt Hansen, Ricardo Tostes Gazzinelli, Benedito Antônio Lopes da Fonseca, Fernando Rosado Spilki, Luiz Tadeu Moraes Figueiredo

Microbiology, Immunology, and Molecular Genetics

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.

Original language	English
Article number	305
Journal	Viruses
Volume	14
Issue number	2
DOIs	https://doi.org/10.3390/v14020305
State	Published - Feb 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Funding

This research was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), (grant numbers 2019/26119-0 (LTMF and BALF) and 2020/05527-0 (LTMF and RTG), and scholarship numbers 2018/09383-3 (MJF)). Rede Corona-ômica BR MCTI/FINEP affiliated to RedeVírus/MCTI. Financiadora de estudos e projetos (FINEP, grant number 01.20.0029.000462/20) and Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (CNPq, grant number 404096/2020-4). Funding: This research was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), (grant numbers 2019/26119-0 (LTMF and BALF) and 2020/05527-0 (LTMF and RTG), and scholarship numbers 2018/09383-3 (MJF)). Rede Corona-ômica BR MCTI/FINEP affiliated to Re-deVírus/MCTI. Financiadora de estudos e projetos (FINEP, grant number 01.20.0029.000462/20) and Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (CNPq, grant number 404096/2020-4).

Funders	Funder number
Fundação de Amparo à Pesquisa do Estado de São Paulo	2019/26119-0, 2020/05527-0, 2018/09383-3
Fundação de Amparo à Pesquisa do Estado de São Paulo
Ministério da Ciência, Tecnologia e Inovação
Conselho Nacional de Desenvolvimento Científico e Tecnológico	404096/2020-4
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Financiadora de Estudos e Projetos	01.20.0029.000462/20
Financiadora de Estudos e Projetos

Keywords

Antibodies
ChAdOx1
Convalescence
CoronaVac
Delta variant
Gamma variant
Neutralization
SARS-CoV-2
Vaccination

ASJC Scopus subject areas

Infectious Diseases
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v14020305

Cite this

@article{35c817b551014215ab16c190a373a1ea,

title = "CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant",

abstract = "The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.",

keywords = "Antibodies, ChAdOx1, Convalescence, CoronaVac, Delta variant, Gamma variant, Neutralization, SARS-CoV-2, Vaccination",

author = "Fumagalli, \{Marcilio Jorge\} and Castro-Jorge, \{Luiza Antunes\} and \{de Souza\}, \{William Marciel\} and \{de Azevedo\}, \{Patrick Orestes\} and Hansen, \{Alana Witt\} and Gazzinelli, \{Ricardo Tostes\} and \{da Fonseca\}, \{Benedito Ant{\^o}nio Lopes\} and Spilki, \{Fernando Rosado\} and Figueiredo, \{Luiz Tadeu Moraes\}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

doi = "10.3390/v14020305",

language = "English",

volume = "14",

number = "2",

}

TY - JOUR

T1 - CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant

AU - Fumagalli, Marcilio Jorge

AU - Castro-Jorge, Luiza Antunes

AU - de Souza, William Marciel

AU - de Azevedo, Patrick Orestes

AU - Hansen, Alana Witt

AU - Gazzinelli, Ricardo Tostes

AU - da Fonseca, Benedito Antônio Lopes

AU - Spilki, Fernando Rosado

AU - Figueiredo, Luiz Tadeu Moraes

PY - 2022/2

Y1 - 2022/2

N2 - The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.

AB - The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.

KW - Antibodies

KW - ChAdOx1

KW - Convalescence

KW - CoronaVac

KW - Delta variant

KW - Gamma variant

KW - Neutralization

KW - SARS-CoV-2

KW - Vaccination

UR - https://www.scopus.com/pages/publications/85124229353

UR - https://www.scopus.com/inward/citedby.url?scp=85124229353&partnerID=8YFLogxK

U2 - 10.3390/v14020305

DO - 10.3390/v14020305

M3 - Article

C2 - 35215895

AN - SCOPUS:85124229353

SN - 1999-4915

VL - 14

JO - Viruses

JF - Viruses

IS - 2

M1 - 305

ER -

CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this